Yield Growth Corp. (CSE:BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that its wholly owned subsidiary, Wright & Well, has developed a dedicated line of CBD products which are set to be manufactured in California this summer. The collection contains less than 0.3% THC, in compliance with the US Farm Bill for legal sale across the United States.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/45071_36a7cb3ee4b47b60-002resize.jpg


Figure 1. Yield Growth to Launch Wright & Well CBD Products in California

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6377/45071_36a7cb3ee4b47b60-002full.jpg

According to Harvard Health Publishing, CBD can be used to effectively treat epilepsy, anxiety, insomnia and chronic pain. The naturally derived compound doesn’t result in a “high” like THC. The Wright & Well CBD line is designed to harness the healing power of cannabis without the psychotropic effects of THC.

The new Wright & Well CBD line includes CBD Full Spectrum Tinctures, Body Balm, Body Gel and Body Oil. Yield Growth approaches product development with uncompromising quality; the unique formulations are founded on Ayurvedic wellness principals, and include Cannabis Sativa Root Extract as a key ingredient, made using Yield Growth subsidiary Urban Juve’s patent pending extraction technology.

Yield Growth has sourced fully certified organic CBD distillate with less than 0.03% THC from a well-established U.S. hemp company that has fair trade relationships with farmers. The CBD is extracted from organic, pesticide-free hemp flower, using an alcohol extraction method. This yields a superior, full spectrum CBD oil with all the cannabinoids and terpenes known to create the “entourage effect.” Full spectrum CBD distillate contains terpenes, flavonoids and multiple cannabinoids. These compounds, along with the terpenes in Yield Growth’s proprietary hemp root extract, complement and enhance each other’s therapeutic benefits to create powerful products.

The CBD products will be manufactured at an FDA registered laboratory and manufacturing facility in California which follows cGMP guidelines. Yield Growth is currently building a CBD product-specific B2C e-commerce website to take consumer orders, and a B2B portal to process retail orders as well. These orders will be routed through Yield Growth’s existing enterprise resource planning system, which will then generate shipping orders to a fulfillment center in California. This development will be built using the underlying architecture of the recently launched, fully functional e-commerce platform www.urbanjuve.com.

Yield Growth is setting itself up to be a major player in the rapidly growing CBD industry. According to an estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022.

“The supply chain, manufacturing and fulfillment processes we have set up in California are scalable, and will allow us to manufacture and sell many CBD products beyond our Wright & Well brand,” says Penny Green, Yield Growth CEO. “Within a few months we will have product manufacturing and distribution channels set up for all three legal streams in the cannabis industry: non-cannabinoid hemp, hemp-derived CBD, and full THC. We are now in talks with potential licensing and joint venture partners to allow us to grow our business at an accelerated rate.”

About The Yield Growth Corp.

The Yield Growth Corp. is disrupting the $4.2 trillion-dollar global wellness market by harnessing the power of hemp- and cannabis-infused products. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy, Aritzia, Coca-Cola and Pepsi Corporation. Its consumer brand, Urban Juve, has signed over 110 retail locations to sell its products in North America and is now launching e-commerce sales in China through Wechat. Urban Juve has signed a sales and marketing alliance with the world’s largest online beauty community, ipsy and Urban Juve products will be included in ipsy Glam Bags. Yield’s THC line of Wright & Well products are launching this month in Oregon through an established distributor with a 400 cannabis retail store network.

Through its subsidiaries, Yield Growth is commercializing over 200 cannabis beauty, wellness, and beverage products. A key ingredient in many of these products is Urvan Juve’s Cannabis Sativa root extract, created using Urban Juve’s proprietary, patent-pending extraction technology. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny Green, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45071

Click here to connect with Yield Growth Corp. (CSE:BOSS) for an Investor Presentation. 

Source: www.newsfilecorp.com

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less